Swintenel
How it worksSample reports
New scan
Swintenel

Product

Start hereSample reports

Company

AboutContactFeedback

Legal

PrivacyTerms

Informational only · Not investment advice

Swintenel
Portfolio checkup

Your book

What you own

Read more

LLY: Price assumes ~2.4× recent revenue growth.

Largest positions

Top holdingLLY22%

Includes 2 other holdings · 18% combined

See all 7 holdings

LLY · 22% of the book

Sector mix

Top sectorHealthcare100%

Healthcare · 100% of the book

Speculation

16%

$18,143

Fundamentals

52%

$56,986

Growth

32%

$34,871

As of Sep 19, 2026 · 7 holdings

This book

Checking this book…

Touched this book

  • LLYUS FDA approves Lilly's breast cancer drug combo
  • LLYEli Lilly and Novo Nordisk Can't Treat This Form of Obesity. Billionaire Stanley Druckenmiller Is Betting Rhythm Pharmaceuticals Can

This week on your book

Nothing dated this week on names over 5%.

Risk shape

What you're actually betting on

You're a earnings-led book — mostly healthcare — and one shared thread touches more than half of your money — that is the main story, not a side sleeve.

  • Healthcare

    LLY, UNH, JNJ, ABBV, PFE…

    100%~$110k

A price-correlation tool may call some names diversifiers. Correlation measures how stocks move; your risk lives in why they would fall. Most of the book shares "Healthcare".

Email me this book

We’ll email a book link you can reuse, plus a one-time sign-in. No password. Later mail uses the same book.

https://swintenel.com/report/healthcare-core

This URL is the book. The email has the same link so you do not have to copy it now.

Portfolio analyst

earnings-led · healthcare · no shared thesis driver · 16% speculation

From your scan

  • No names in this book report in the next 14 days (earnings calendar checked).
  • Your book moves -0.3× USD, long-duration.
  • In past nasdaq drawdown window episodes, books like yours fell ~10.1% over 3 months (base rate, not a forecast).
Descriptive context only — not investment advice. Swintenel never recommends trades.
Swintenel

Product

Start hereSample reports

Company

AboutContactFeedback

Legal

PrivacyTerms

Informational only · Not investment advice